Nanomaterials for targeted treatment of pulmonary tissue
AssigneeThe University of North Carolina at Chapel Hill
InventorsMelina R. Kibbe, Kathleen Marulanda, Alexandra Mercel, Nick Tsihlis, Thomas Gregory Wyatt
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for targeted drug delivery to treat pulmonary injury. In particular, provided herein are nanoscale delivery vehicles for: drugs that treat pulmonary injury. Also provided here in are methods of generating the nanoscale delivery vehicles and compositions thereof.
Claims28
A peptide amphiphile comprising:
- (a) a hydrophobic non-peptidic segment;
- (b) a β-sheet-forming peptide segment;
- (c) a charged peptide segment;
- (d) a targeting moiety, wherein the targeting moiety localizes to pulmonary tissue;
- wherein the hydrophobic non-peptidic segment is covalently attached to the N-terminus or C-terminus of the β-sheet-forming peptide segment;
- wherein the β-sheet-forming peptide segment is covalently attached to the targeting moiety;
- and wherein the charged peptide segment is covalently attached to the targeting moiety.
9-16. (canceled)
19-22. (canceled)
26-33. (canceled)
(canceled)
(canceled)
39-42. (canceled)
44-48. (canceled)
A method of making a peptide amphiphile (PA) based nanomaterial which targets receptor for advanced glycation end products (RAGE) or angiotensin-converting enzyme (ACE) comprising:
- synthesizing targeting PA molecules via solid phase peptide synthesis comprising contacting a RAGE-targeting peptide with a diluent PA backbone;
- purifying the PA molecules;
- dissolving targeting PA molecules and with a diluent PA in a molar ratio in a solvent;
- removing the solvent;
- and
- forming the nanomaterial via self-assembly by resuspending the mixture of PA molecules in liquid at physiological pH.
51-57. (canceled)
Dependencies are inferred from the claim text.